|
Orthologous residues
|
|
LC3A (human): S12‑p, LC3A (mouse): S12‑p, LC3A (rat): S12‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
neuroblastoma
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical), SH-SY5Y (neural crest)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (human)
|
pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
forskolin
|
|
|
|
increase
|
|
|
H-89
|
forskolin
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
|
|
|
decrease
|
|
|
MPP+
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
autophagy, altered
|